What is CODAGENIX?
Codagenix operates at the intersection of synthetic biology and global health, specializing in the design of precise, live-attenuated vaccines. By utilizing a unique computational approach to edit viral genomes, the company addresses critical gaps in infectious disease prevention. Their platform is engineered to provide the robust immune response characteristic of live-attenuated viruses while mitigating the risks typically associated with traditional vaccine development. As a high-growth biotechnology entity, Codagenix is strategically positioned to disrupt the vaccine market, offering scalable solutions that are essential for responding to emerging global health threats and pandemic preparedness.
How much funding has CODAGENIX raised?
CODAGENIX has raised a total of $49M across 5 funding rounds:
Multiple Rounds
$2M
Series A
$2M
Series B
$45M
Grant (2014): $222K with participation from National Institutes of Health
Unspecified (2014): $100K led by Accelerate Long Island
Angel/Seed (2014): $1.7M supported by National Institutes of Health and State of New York - Empire State Development
Series A (2015): $2M featuring Topspin Partners
Series B (2023): $45M backed by Euclidean Capital, Adjuvant Capital, and Serum Institute of India Pvt. Ltd.
Key Investors in CODAGENIX
Euclidean Capital
An investment firm currently expanding its portfolio, focusing on strategic capital deployment and long-term value creation within the innovation sector.
Adjuvant Capital
A venture capital firm dedicated to financing life science technologies that address high-burden public health challenges, with a specific focus on infectious diseases and global health equity.
Serum Institute of India Pvt. Ltd.
A global leader in the manufacturing of immunobiological drugs and vaccines, providing critical industrial expertise and infrastructure to support large-scale vaccine production.
What's next for CODAGENIX?
Following this major enterprise-level funding, Codagenix is poised to accelerate its clinical pipeline and expand its manufacturing capabilities. The strategic focus will likely shift toward scaling its therapeutic platform to address high-burden infectious diseases, leveraging the expertise of its diverse investor base. By integrating advanced synthetic biology with global distribution networks, the company aims to transition from a research-intensive startup to a commercial-stage powerhouse. Future growth will be defined by the successful navigation of regulatory pathways and the continued validation of its vaccine candidates in human trials, ensuring that their innovative technology reaches underserved populations worldwide.
See full CODAGENIX company page
